Dendreon, the Day That Could Have Been and What to Expect Now

by Jon C. Ogg
24/7 Wall St.



At about 5:20 this morning after rolling the calendar a day over to see the notes, something stood out like a sore thumb: DENDREON (DNDN) DO OR DIE DATE! The truth is that the May 15 date was on the "by May 15" date, and we all know that last week's bomb from the FDA came out resulting in what will be very long delays for the company before we know if the FDA will approve Provenge for late-stage prostate cancer victims.

So, What do Dendreon shareholders have to look forward to and what should they expect from here? The "approvable letter" is a far batter response than a non-approvable letter" that is the true kiss of death, but the delays come at a time where the company is going to have to go into cash survival mode.


Continue article at 247WallSt.com




RELATED READING:
- Rantasorous Rx
- Comments From Dendreon's Conference Call (May 10, 2007)
- Dendreon Gets Complete Response Letter
- Dendreon Nailed by FDA

___________________